MIRUM PHARMACEUTICALS, INC.

(MIRM)
  Rapport
Temps Différé Nasdaq  -  25/05 22:00:00
25.70 USD   +1.74%
24/05MIRUM PHARMACEUTICALS, INC. : SVB Securities LLC optimiste sur le dossier
ZM
23/05MIRUM PHARMACEUTICALS, INC. : HC Wainwright favorable sur le dossier
ZM
23/05Mirum Pharmaceuticals acquiert Satiogen Pharmaceuticals dans le cadre d'une transaction en espèces et en actions ; les actions chutent.
MT
SynthèseCotationsGraphiquesActualitésNotationsAgendaSociétéFinancesConsensusRévisionsDérivésFonds 
SynthèseToute l'actualitéReco analystesAutres languesCommuniquésPublications officiellesActualités du secteur
Actualités dans d'autres langues sur MIRUM PHARMACEUTICALS, INC.
23/05Mirum Pharmaceuticals Acquires Satiogen Pharmaceuticals in Cash-and-Stock Deal; Shares ..
23/05MIRUM PHARMACEUTICALS, INC. : Other Events (form 8-K)
23/05Mirum Pharmaceuticals Acquires Satiogen Pharmaceuticals
23/05Mirum Pharmaceuticals, Inc. acquired Satiogen Pharmaceuticals, Inc. for approximately $..
19/05Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
11/05Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/05MIRUM PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Conditio..
05/05TRANSCRIPT : Mirum Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 05, 2022
05/05Mirum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Busines..
05/05Mirum Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March ..
05/05Earnings Flash (MIRM) MIRUM PHARMACEUTICALS Reports Q1 Revenue $12.9M, vs. Street Est o..
02/05Mirum Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Confere..
09/04Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29/03CANbridge Pharmaceuticals Inc. and Mirum Pharmaceuticals Sign an Exclusive License Agre..
11/03Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
11/03Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/03TRANSCRIPT : Mirum Pharmaceuticals, Inc., Q4 2021 Earnings Call, Mar 09, 2022
09/03MIRUM PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Conditio..
09/03Mirum Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 3..
09/03MIRUM PHARMACEUTICALS : Reports Fourth Quarter and Year-End 2021 Financial Results and Pro..
09/03Mirum Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended Decem..
09/03Earnings Flash (MIRM) MIRUM PHARMACEUTICALS Reports Q4 Revenue $3.1M
09/03Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Pr..
02/03Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End Business Results for 2021..
11/02Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/02Mirum Pharmaceuticals to Present at SVB Leerink 11th Annual Global Healthcare Conferenc..
19/01CANbridge Pharmaceuticals CAN108 New Drug Application (NDA), for Alagille Syndrome, Acc..
11/01TRANSCRIPT : Mirum Pharmaceuticals, Inc. Presents at JPMorgan 40th Annual Healthcare Confe..
11/01Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
11/01MIRUM PHARMACEUTICALS : Provides Business Update and Highlights Key 2022 Corporate Milesto..
11/01MIRUM PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Regulation FD..
11/01Mirum Pharmaceuticals Provides Business Update and Highlights Key 2022 Corporate Milest..
11/01Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/01Mirum Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference o..
03/01Immix Biopharma Shares More Than Double on FDA Designation
03/01Immix Biopharma Shares Soar Premarket After Key FDA Designation
2021MIRUM PHARMACEUTICALS : Completion of Acquisition or Disposition of Assets - Form 8-K
2021MIRUM PHARMACEUTICALS, INC. : Completion of Acquisition or Disposition of Assets (form 8-K..
2021MIRUM PHARMACEUTICALS, INC.(NASDAQGM : MIRM) added to NASDAQ Biotechnology Index
2021Mirum Pharmaceuticals to be Added to Nasdaq Biotechnology Index
2021Mirum Pharmaceuticals Added to NASDAQ Biotechnology Index
2021LIVMARLI (maralixibat) Presentations Show Improvements in Quality of Life Measures in A..
2021LIVMARLI (maralixibat) Presentations Show Improvements in Quality of Life Measures in A..
2021Mirum Pharmaceuticals to Present LIVMARLI™ (maralixibat) Analyses at NASPGHAN 202..
2021INSIDER BUY : Mirum Pharmaceuticals
2021Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
2021MIRUM PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Financial Statem..
2021Longeveron Shares Soar 120% on Key FDA Designation
2021Mirum to Sell Livmarli Priority Review Voucher for $110 Million
2021Mirum Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher
2021MIRUM PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Conditio..
2021TRANSCRIPT : Mirum Pharmaceuticals, Inc., Q3 2021 Earnings Call, Nov 15, 2021
2021MIRUM PHARMACEUTICALS : Reports Third Quarter 2021 Financial Results and Provides Business..
2021Mirum Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Mon..
2021Mirum Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Busines..
2021Six-Year Natural History Comparison with Mirum's LIVMARLI (maralixibat) Demonstrates Ev..
2021Mirum Pharmaceuticals, Inc. Announces That A New Analysis Comparing Pooled Livmarli? (M..
2021Mirum Pharmaceuticals to Report Third Quarter 2021 Financial Results and Host Conferenc..
2021Mirum Pharmaceuticals to Present Maralixibat Data at Scientific Conference
2021New LIVMARLI™ (maralixibat) Data to be Showcased at AASLD The Liver Meeting® 2021
2021The Lancet Publishes Data From Mirum Pharmaceuticals' ICONIC Pivotal Study of Maralixib..
2021The Lancet Publishes Data From Mirum Pharmaceuticals' ICONIC Pivotal Study of Maralixib..
2021MIRUM PHARMACEUTICALS : U.S. FDA Approves LIVMARLI (maralixibat) as the First and Only App..
2021MIRUM PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Other Events, Fi..
2021TRANSCRIPT : Mirum Pharmaceuticals, Inc. - Special Call
2021MIRUM PHARMACEUTICALS : Gets FDA's OK for Livmarli Oral Solution to Treat Chronic Itch in ..
2021MIRUM PHARMACEUTICALS : oral drug becomes first U.S. approved Alagille syndrome therapy
2021MIRUM PHARMACEUTICALS : FDA approves Mirum Pharma's drug for itching associated with rare ..
2021MIRUM PHARMACEUTICALS : U.S. FDA Approves LIVMARLI (maralixibat) as the First and Only App..
2021Mirum Pharmaceuticals, Inc Receives U.S. Food and Drug Administration Approval LIVMARLI..
2021MIRUM PHARMACEUTICALS : Halted on Pending News; Shares Up 3% in Recent Trading
2021MIRUM PHARMA : FDA OKs Livmarli to Treat Cholestatic Pruritus in Certain Patients
2021MIRUM PHARMACEUTICALS : Partners With Takeda Over Developing, Commercializing Liver Diseas..
2021Mirum Inks Japan License for Maralixibat With Takeda
2021MIRUM PHARMACEUTICALS : Seeks Marketing Approval for Liver Disease Drug Candidate in Europ..
1  2  3  4Suiv.
Prochain événement sur MIRUM PHARMACEUTICALS, INC.